No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

被引：0
|
作者：
D. Tomalik-Scharte
O. Doroshyenko
J. Kirchheiner
A. Jetter
A. Lazar
T. Klaassen
D. Frank
C. Wyen
G. Fätkenheuer
U. Fuhr
机构：
[1] University of Cologne,Department of Pharmacology, Clinical Pharmacology
[2] University of Ulm,Department of Pharmacology of Natural Products and Clinical Pharmacology
[3] University Hospital Zürich,Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine
[4] University of Cologne,Department I of Internal Medicine, University Hospital
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Midazolam; Alfentanil; CYP3A Activity; CYP3A5 Expression; CYP3A5 Substrate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1035
页数：2
相关论文
共 50 条
  • [41] A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Lee, Su-Jun
    van der Heiden, Ilse P.
    Goldstein, Joyce A.
    van Schaik, Ron H. N.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) : 67 - 71
  • [42] Possible impact of CYP3A5 polymorphisms on carbamazepine metabolism
    Magliulo, L.
    Viana, M.
    Scordo, M. G.
    Fallarini, S.
    Dahl, M-L.
    Monaco, F.
    Lombardi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 150 - 150
  • [43] In vitro metabolism of cyclosporine A by human kidney CYP3A5
    Dai, Y
    Iwanaga, K
    Lin, YS
    Hebert, MF
    Davis, CL
    Huang, WL
    Kharasch, ED
    Thummel, KE
    BIOCHEMICAL PHARMACOLOGY, 2004, 68 (09) : 1889 - 1902
  • [44] The genotype-phenotype association of CYP3A4 and CYP3A5 polymorphisms to midazolam clearance in vivo
    He, P
    Court, MH
    Greenblatt, DJ
    von Moltke, LL
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1209 - 1209
  • [45] The genotype-phenotype association of CYP3A4 and CYP3A5 polymorphisms to midazolam hydroxylation in vivo
    He, P
    Court, MH
    Greenblatt, DJ
    von Moltke, LL
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [46] Territrems B and C metabolism in human liver microsomes: Major role of CYP3A4 and CYP3A5
    Peng, FC
    Chang, CC
    Yang, CY
    Edwards, RJ
    Doehmer, J
    TOXICOLOGY, 2006, 218 (2-3) : 172 - 185
  • [47] Tacrolimus pharmacokinetics and pharmacodynamics in kidney transplantation: The role of CYP3A5 polymorphism in a pediatric population
    Ghio, L.
    Ferraresso, M.
    Tirelli, S.
    Grillo, P.
    Belingheri, M.
    Martina, V.
    Torresani, E.
    Edefonti, A.
    PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1588 - 1588
  • [48] Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients
    Chu, Xiao-man
    Hao, Hai-ping
    Wang, Guang-ji
    Guo, Lian-qing
    Min, Pei-qing
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (11) : 1504 - 1508
  • [49] CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression
    Pasari, Amit S.
    Balwani, Manish R.
    Gurjar, Prasad
    Bawankule, Charulata
    Bhawane, Amol
    Tolani, Priyanka
    Kashiv, Pranjal
    Dubey, Shubham
    Katekhaye, Vijay M.
    TRANSPLANTATION PROCEEDINGS, 2023, 55 (05) : 1305 - 1309
  • [50] Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
    Dai, Y
    Hebert, MF
    Isoherranen, N
    Davis, CL
    Marsh, C
    Shen, DD
    Thummel, KE
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) : 836 - 847
12345